HTG Molecular Diagnostics, Inc.
NASDAQ Capital MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- John L. Lubniewski
- Full Time Employees
- 53
- Sector
- Healthcare
- Industry
- Medical - Diagnostics & Research
- Address
- 3430 East Global Loop Tucson AZ United States of America 85706
- IPO Date
- May 6, 2015
- CIK
- 0001169987
- Website
- htgmolecular.com
- Similar Companies
- Business
- HTG Molecular Diagnostics, Inc. (HTGM) develops and commercializes molecular profiling platforms, instruments, consumables, and software for precision medicine applications, including next-generation sequencing-based sample processing for miRNA, mRNA, fusions, and DNA analysis from small clinical samples such as FFPE tissue or liquid biopsies. The company's core offerings center on the HTG EdgeSeq system and related assays, including the HTG Transcriptome Panel for whole transcriptome profiling; HTG EdgeSeq Precision Immuno-Oncology Panel; HTG EdgeSeq miRNA Whole-Transcriptome Assay; HTG EdgeSeq DLBCL Cell of Origin Assay (EU); HTG EdgeSeq Oncology Biomarker Panel; HTG Immune Response Panel; and HTG Mouse mRNA Tumor Response Panel; as well as product-related services like RUO sample processing in its VERI/O laboratory and custom assay design. HTG markets these solutions to biopharmaceutical companies, academic research centers, molecular testing laboratories, and clinical trial organizations in the healthcare, therapeutics, biotechnology, and drug discovery sectors, with direct distribution in the United States and Europe plus international distributors. Founded in 1997 and headquartered in Tucson, Arizona, the company operates primarily in the diagnostics and research segment of the healthcare industry. In recent major developments, HTG filed for Chapter 11 bankruptcy protection on June 5, 2023, which converted to Chapter 7 liquidation on May 21, 2025, amid no ongoing operations or recovery prospects.
Why Is HTG Molecular Diagnostics (HTGM) Stock Down 42% Today?
HTG Molecular Diagnostics Provides Highlights of its Second Event in Drug Discovery KOL Webcast Series
What Is Going on With HTG Molecular Diagnostics (HTGM) Stock Today?
3 Top Biotech Penny Stocks Under $3 To Watch Right Now
Penny Stocks To Buy Now? 10 Stocks Under $1 To Watch
How to Conduct Due Diligence on Penny Stocks, 3 Tips
7 Hot Penny Stocks Under $1 To Watch This Week
Three Small-Cap Biotech Stocks to Consider Now
Dear HTGM Stock Fans, Mark Your Calendars for Dec. 13
HTG Molecular Diagnostics Announces the Next Event in its RNA Profiling in Drug Discovery KOL Webcast Series
HTG Molecular Diagnostics, Inc. (HTGM) Reports Q3 Loss, Misses Revenue Estimates
HTG Molecular Diagnostics, Inc. (HTGM) Moves to Buy: Rationale Behind the Upgrade
HTG Molecular Diagnostics, Inc. (HTGM) CEO John Lubniewski on Q2 2022 Results - Earnings Call Transcript
Penny Stocks To Buy? 4 Short Squeeze Stocks To Watch After CPI Data
Check These 3 Penny Stocks Out For Your Watchlist
Best Penny Stocks To Buy? 4 Low Float Stocks To Watch Now
Top Penny Stocks to Buy Today? 3 to Watch Right Now
Best Penny Stocks to Buy Right Now? 3 to Watch in July 2022
Best Penny Stocks For July 2022? 5 To Watch Right Now
HTG Molecular Diagnostics to Participate in the H.C. Wainwright Global Investment Conference